CervoMed Inc. (CRVO) stock
CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.50−0.17 (-10.18%)
Close on Nov 17, 2026Market cap $22.68MP/E –Yield –
CervoMed profit margin
Profit margin (net margin) is net income as a percentage of revenue.
CervoMed's profit margin for the twelve months ending Jun 30, 2026 was -9160.9%. For fiscal 2025 it was -673.1%, against -167.3% the year before. The highest annual figure on record is -30.4% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -673.1% | −505.8 |
| FY2024 | Dec 31, 2024 | -167.3% | −136.9 |
| FY2023 | Dec 31, 2023 | -30.4% | +3399.3 |
| FY2013 | Dec 31, 2013 | -3429.7% | −1595.7 |
| FY2012 | Dec 31, 2012 | -1833.9% | +2133.9 |
| FY2011 | Dec 31, 2011 | -3967.9% | +16957.3 |
| FY2010 | Dec 31, 2010 | -20925.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -92680.4% | −92370.2 |
| Q3 FY2025 | Sep 30, 2025 | -2395.3% | −2150.3 |
| Q2 FY2025 | Jun 30, 2025 | -356.1% | −285.6 |
| Q1 FY2025 | Mar 31, 2025 | -255.2% | −148.1 |
| Q4 FY2024 | Dec 31, 2024 | -310.2% | −215.3 |
| Q3 FY2024 | Sep 30, 2024 | -245.1% | −385.9 |
| Q2 FY2024 | Jun 30, 2024 | -70.4% | +12.4 |
| Q1 FY2024 | Mar 31, 2024 | -107.1% | −69.2 |
| Q4 FY2023 | Dec 31, 2023 | -94.9% | – |
| Q3 FY2023 | Sep 30, 2023 | 140.9% | – |
| Q2 FY2023 | Jun 30, 2023 | -82.9% | – |
| Q1 FY2023 | Mar 31, 2023 | -38.0% | – |
See a number that looks wrong?